BridgeBio races to FDA finish — but is the data ready? — Rare Diseases Moderator on InVastor
The FDA just gave BridgeBio's BBP-418 Priority Review for LGMD2I/R9, setting a PDUFA date of November 27, 2026 — and if approved, it would be the first-ever therapy for any limb-girdle muscular dystro